Latest Breaking News On - Karsten kleine - Page 17 : comparemela.com

F Hoffmann-La Roche Ltd: Positive Phase III results for Roche s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis

F Hoffmann-La Roche Ltd: Positive Phase III results for Roche s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesKirti pandeyNathalie altermattSabine borngrSileia urechLevi garrawayBirgit masjostBruno eschliKarsten kleineGerard tobinLoren kalmRoche group media relationsHead of global product developmentRoche groupChief medical officerGlobal product

F Hoffmann-La Roche Ltd: European Commission approves Roche s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma

F Hoffmann-La Roche Ltd: European Commission approves Roche s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesSileia urechGerard tobinBirgit masjostSabine borngrBruno eschliMichael dickinsonLoren kalmNathalie altermattKarsten kleineLevi garrawayKirti pandeyRoche groupEuropean medicines agency summary of product characteristicsPeter maccallum cancer centreEuropean commission

European Commission approves Roche s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma

Basel, 11 July 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has granted conditional marketing authorisation for…

United statesLoren kalmMichael dickinsonNathalie altermattKirti pandeyKarsten kleineSileia urechLevi garrawayRoche groupPeter maccallum cancer centreEuropean commissionHead of global product developmentRoche group media relationsEuropean medicines agency summary of product characteristicsDrug administrationWorld health organization

F Hoffmann-La Roche Ltd: New data show Roche s subcutaneously administered crovalimab achieved disease control and was well-tolerated in people with paroxysmal nocturnal haemoglobinuria (PNH)

The COMMODORE 2 study demonstrated that subcutaneous crovalimab every four weeks was non-inferior to intravenous eculizumab every two weeks, with comparable safety, in people new to C5 inhibitors1Monthly

United statesGerard tobinNathalie altermattLevi garrawaySileia urechLoren kalmBruno eschliSabine borngrBirgit masjostKarsten kleineHead of global product developmentRoche group media relationsChina national medical products administrationAmerican societyRoche groupAmerican society of hematology

New data show Roche s subcutaneously administered crovalimab achieved disease control and was well-tolerated in people with paroxysmal nocturnal haemoglobinuria (PNH)

The COMMODORE 2 study demonstrated that subcutaneous crovalimab every four weeks was non-inferior to intravenous eculizumab every two weeks, with comparable safety, in people new to C5. | June 9, 2023

United kingdomUnited statesNathalie altermattKarsten kleineLevi garrawayLoren kalmSileia urechChugai pharmaceutical co ltdRoche groupPresentation at european hematology associationHead of global product developmentAmerican societyRoche group media relationsAmerican society of hematologyEuropean hematology associationNational organization for rare diseases